| Q48529841 | 13th Annual C. Walton Lillehei Memorial Lecture--Invisible problems in cardiovascular surgery: what we can learn from prospective observational studies? |
| Q35068814 | A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: the Rancho Bernardo Study |
| Q43917968 | A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function |
| Q34573282 | A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects |
| Q35948653 | Adverse neoplastic and cardiovascular outcomes of HRT: the validity of the evidence |
| Q44470911 | Alcohol, aging, and cognitive performance: a cross-cultural comparison |
| Q45078106 | Alcohol, gender, and cognitive performance: a longitudinal study comparing older Japanese and non-Hispanic white Americans |
| Q47700996 | An introduction to instrumental variable assumptions, validation and estimation. |
| Q41696431 | Association between bone mineral density and cognitive decline in older women |
| Q36631882 | Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. |
| Q34585847 | Cardioprotective benefits of hormone replacement therapy |
| Q36885553 | Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? |
| Q57626354 | Cardiovascular Health Promotion in Aging Women: Validating a Population Health Approach |
| Q61387330 | Changes in plasma lipids and lipoproteins associated with starting or stopping postmenopausal hormone replacement therapy |
| Q39446259 | Choosing the most appropriate treatment for stable angina. Safety considerations |
| Q35688610 | Clinical pharmacology of anti-Alzheimer drugs |
| Q33761005 | Cognitive benefits of hormone therapy: cardiovascular factors and healthy-user bias |
| Q46199233 | Cognitive decline in women in relation to non-protein-bound oestradiol concentrations |
| Q42394794 | Coronary heart disease, the menopause, and hormone replacement therapy |
| Q57268423 | Detection method and breast carcinoma histology |
| Q40714159 | Disparities in hormone replacement therapy use by socioeconomic status in a primary care population |
| Q67551067 | Do current regimes of hormone replacement therapy protect against subsequent fractures? |
| Q44223626 | Effects of hormone replacement therapy on cardiovascular responses in postmenopausal women with and without type 2 diabetes |
| Q46793921 | Effects of ultra-low-dose estrogen therapy on muscle and physical function in older women |
| Q51980915 | Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women. |
| Q40877167 | Epidemiological overview of oestrogen replacement and cardiovascular disease |
| Q40475922 | Epidemiology of osteoporosis. Implications for drug therapy. |
| Q53028018 | Estrogen after ischemic stroke: clinical basis and design of the Women's Estrogen for Stroke Trial. |
| Q34767487 | Estrogen and Alzheimer's disease: the story so far. |
| Q35812293 | Estrogen and Cardiovascular Disease: Is Timing Everything? |
| Q35109605 | Estrogen and Cognitive Functioning in Women |
| Q73677510 | Estrogen and heart disease: trials to prevent tribulations |
| Q77571415 | Estrogen for women at varying risk of coronary disease |
| Q74137301 | Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies |
| Q72561225 | Estrogen therapy for the prevention of coronary heart disease: what are the facts? |
| Q80815527 | Estrogens and Stroke: Use of Oral Contraceptives and Postmenopausal Use of Estrogen: Current Recommendations |
| Q36793658 | Factors contributing to skeletal health of postmenopausal Mexican-American women |
| Q37090625 | Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement |
| Q40498624 | Fracture protection provided by long-term estrogen treatment |
| Q43574794 | Health status of hormone replacement therapy users and non-users as determined by the SF-36 quality-of-life dimension. |
| Q34186876 | Healthy aging. A women's issue. |
| Q34799001 | Healthy user and related biases in observational studies of preventive interventions: a primer for physicians |
| Q46000257 | Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. |
| Q33721739 | History of hot flashes and aortic calcification among postmenopausal women |
| Q41683855 | Homoeopathic treatment during the menopause |
| Q40621286 | Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease |
| Q42757321 | Hormone replacement therapy again. Risk-benefit relation differs between populations and individuals |
| Q40877118 | Hormone replacement therapy and cancer |
| Q47963206 | Hormone replacement therapy and cancer risk: A systematic analysis from a network of case‐control studies |
| Q35596294 | Hormone replacement therapy and cardioprotection: the end of the tale? |
| Q40434852 | Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint |
| Q52894947 | Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. |
| Q36144161 | Hormone replacement therapy and risk of acute myocardial infarction : a review of the literature. |
| Q43190397 | Hormone replacement therapy for all? Long-term randomised controlled trial is needed |
| Q36599670 | Hormone replacement therapy for all? Not for everybody |
| Q24242542 | Hormone replacement therapy for cognitive function in postmenopausal women |
| Q62899568 | Hormone replacement therapy in postmenopausal women protects against smoking-induced changes in vascular structure and function |
| Q46077959 | Hormone replacement therapy is associated with improved survival in women with advanced heart failure |
| Q24241789 | Hormone replacement therapy to maintain cognitive function in women with dementia |
| Q35419972 | Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives |
| Q60728578 | Hormone replacement therapy: the need for reconsideration |
| Q33231108 | Hormone therapy and cardiovascular disease: a systematic review and meta-analysis |
| Q34417085 | Hormone therapy and heart disease after the menopause |
| Q35948667 | Hormones and bone health in postmenopausal women |
| Q34675309 | Hormones and heart disease: what we thought, what we have learned, what we still need to know |
| Q41738338 | Hormones and the cardiologist |
| Q35979363 | Hormones, menopause, and heart disease: making sense of the Women's Health Initiative |
| Q73559562 | Immune effects of hormone replacement therapy in post-menopausal women |
| Q64069684 | Impact of Smoking Status on Stroke Recurrence |
| Q74194564 | Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up |
| Q45157244 | Is antioxidant use protective of cognitive function in the community-dwelling elderly? |
| Q34714748 | Issues of hormone replacement therapy and cardiovascular disease for elderly women |
| Q50722414 | Knowledge and attitude towards personal health care and menopause among women with ischemic heart disease undergoing coronary angiography. |
| Q43944129 | Lifestyle factors and choice of hormone replacement therapy among Danish nurses |
| Q41727278 | Long-term estrogen replacement therapy is associated with improved exercise capacity in postmenopausal women without known coronary artery disease |
| Q36053335 | Low use of long-term hormone replacement therapy in Denmark |
| Q46169628 | Mammography using in a community-based sample of older women |
| Q41528365 | Medicalization of Menopause and Public Health |
| Q71519834 | Menopause |
| Q41664444 | Menopause and post-menopause |
| Q34341910 | Menopause, hormone replacement therapy and cancer |
| Q34328229 | Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis |
| Q36615213 | Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study |
| Q90646986 | Negative controls to detect uncontrolled confounding in observational studies of mammographic screening comparing participants and non-participants |
| Q47647625 | New hope for hormone replacement and the heart? |
| Q58294084 | Oestrogen replacement therapy and coronary heart disease |
| Q40877161 | Oestrogens and atherosclerotic vascular disease--lipid factors |
| Q33545893 | Oral contraceptives and colorectal tumors. A review of epidemiologic studies |
| Q37477171 | Overweight and effect of hormone replacement therapy on lipid profiles in postmenopausal women |
| Q33644539 | Phyto-oestrogens: a potential role in the prevention of CHD? |
| Q34746437 | Postmenopausal estrogen therapy and depressive symptoms in older women |
| Q35245034 | Postmenopausal hormone replacement therapy |
| Q36645889 | Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women |
| Q33757741 | Postmenopausal hormone therapy, SERMs, and coronary heart disease in women |
| Q35692889 | Postmenopausal hormone therapy: a concise guide to therapeutic uses, formulations, risks, and alternatives |
| Q50780867 | Postmenopausal hormone therapy: who now takes it and do they differ from non-users? |
| Q44183852 | Prevalence and determinants of hormone replacement therapy in German women 1984-1995. |
| Q34272961 | Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women |
| Q37453973 | Progress in osteoporosis and fracture prevention: focus on postmenopausal women |
| Q38750749 | Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study |
| Q74020033 | Relation between hormone replacement therapy in women and coronary artery disease estimated by electron beam tomography |
| Q33557595 | Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study |
| Q51953358 | Relationship between psychosocial factors and health behaviours for women experiencing menopause. |
| Q34198010 | Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies |
| Q48427385 | Rethinking estrogen and the brain |
| Q73765058 | Self-rated health, life satisfaction and personal characteristics of post-menopausal women under estrogen replacement therapy |
| Q36854152 | Sex hormones and the cardiovascular system: effects on arterial function in women. |
| Q48569413 | Smoking cessation and outcome after ischemic stroke or TIA. |
| Q40812580 | The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women |
| Q50907961 | The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women. |
| Q43584270 | The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial |
| Q73091606 | The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group |
| Q41507873 | The effects of hormone replacement therapy on coronary heart disease |
| Q36673647 | The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women |
| Q34504839 | The medicalization of menopause: critique and consequences |
| Q35134598 | The menopause and HRT. Hormone replacement therapy, cardiovascular and cerebrovascular disease. |
| Q40892229 | The menopause: health implications and clinical management |
| Q37385026 | The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women |
| Q57606043 | Transdermal estrogen replacement therapy and plasma lipids in 693 French women |
| Q37014593 | Treatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity |
| Q39473171 | Use of hormone replacement therapy by Melbourne women |
| Q71529814 | Why cardiologists should be interested in estrogen |
| Q47332234 | Why do professionals disagree? The case of hormone replacement therapy and coronary heart disease prevention |
| Q33704462 | Why do women doctors in the UK take hormone replacement therapy? |
| Q33213520 | Women's perceptions of hormone replacement therapy: risks and benefits (1980-2002). A literature review. |
| Q52897432 | [Estrogens for prevention of coronary heart disease?]. |